Search results
Showing 61 to 75 of 208 results for myocardial infarction
Cardiovascular disease: risk assessment and reduction, including lipid modification (NG238)
This guideline covers identifying and assessing risk of cardiovascular disease (CVD) in adults without established CVD. It covers lifestyle changes and lipid-lowering treatment (including statins) for primary and secondary prevention of CVD, and includes guidance for people who also have diabetes or chronic kidney disease.
Evidence-based recommendations on edoxaban (Lixiana) for preventing stroke and systemic embolism in adults with non-valvular atrial fibrillation.
This guideline covers identifying and treating primary hypertension (high blood pressure) in people aged 18 and over, including people with type 2 diabetes. It aims to reduce the risk of cardiovascular problems such as heart attacks and strokes by helping healthcare professionals to diagnose hypertension accurately and treat it effectively.
Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia (TA393)
Evidence-based recommendations on alirocumab (Praluent) for treating primary hypercholesterolaemia or mixed dyslipidaemia in adults.
Evidence-based recommendations on transcervical extracorporeal reverse flow neuroprotection for reducing the risk of stroke during carotid artery stenting in adults. This involves reversing blood flow away from the brain and filtering the blood to remove any debris.
Evidence-based recommendations on thoracoscopically assisted mitral valve surgery. This involves repairing a defective valve through one or more small incisions between the ribs rather than one large incision through the breastbone (sternum).
View recommendations for HTG157Show all sections
Sections for HTG157
device durability; and the complications of hypertension, such as myocardial infarction and stroke. Any explanatory notes(if applicable)...
Discontinued Reference number: GID-TA10337
complications in the longer term. This includes an increased risk of myocardial infarction and death with some types of bioresorbable...
Evidence-based recommendations on intravascular lithotripsy to treat calcified coronary arteries during percutaneous coronary intervention. This involves using ultrasound shockwaves to break up hard deposits in the arteries, to allow blood to flow more freely.
View recommendations for HTG740Show all sections
Cryoablation for atrial fibrillation in association with other cardiac surgery (HTG74)
Evidence-based recommendations on cryoablation for atrial fibrillation in association with other cardiac surgery. This involves using a probe to freeze the heart tissue to scar it and interrupt the abnormal electrical signals.
View recommendations for HTG74Show all sections
Sections for HTG74
Evidence-based recommendations on dabigatran etexilate (Pradaxa) for preventing stroke and systemic embolism in adults with non-valvular atrial fibrillation.
Adefovir dipivoxil and peginterferon alfa-2a for the treatment of chronic hepatitis B (TA96)
Evidence-based recommendations on adefovir dipivoxil (Hepsera) and peginterferon alfa-2a (Pegasys) for treating chronic hepatitis B in adults.
CytoSorb for reducing risk of bleeding during cardiac surgery (MIB249)
NICE has developed a medtech innovation briefing (MIB) on CytoSorb for reducing risk of bleeding during cardiac surgery .
Valve-in-valve TAVI for aortic bioprosthetic valve dysfunction (HTG518)
Evidence-based recommendations on valve-in-valve transcatheter aortic valve implantation (ViV-TAVI) for aortic bioprosthetic valve dysfunction in adults. This involves placing a new bioprosthetic valve inside a failing bioprosthetic valve.
View recommendations for HTG518Show all sections